[New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer]

Bull Cancer. 2022 Oct;109(10):988-989. doi: 10.1016/j.bulcan.2022.06.006. Epub 2022 Jul 22.

[Article in French]

Authors

Marie-Sophie Minot-This¹, Antoine Deleuze²

Affiliations

¹ Institut Gustave Roussy, département d'oncologie médicale, comité sénologie, Villejuif, France. Electronic address: [email protected].
² Centre Eugène Marquis, département d'oncologie médicale, Rennes, France.

PMID: 35871860
DOI: 10.1016/j.bulcan.2022.06.006

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant
Drug Approval
Female
Humans
Neoadjuvant Therapy
Triple Negative Breast Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab